Newborn screening for X-Linked adrenoleukodystrophy

Ann B. Moser, Richard O. Jones, Walter C. Hubbard, Silvia Tortorelli, Joseph J. Orsini, Michele Caggana, Beth H. Vogel, Gerald V. Raymond

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Early diagnosis of males with X-linked adrenoleukodystrophy (X-ALD) is essential for preventing loss of life due to adrenal insufficiency and for timely therapy of the childhood cerebral form of X-ALD with hematopoietic cell transplantation. This article describes X-ALD, the current therapies, the history of the development of the newborn screening test, the approval by the Secretary of Health and Human Services for the addition of X-ALD newborn screening to the recommended uniform panel of disorders screened as newborns (RUSP) and the successful implementation of X-ALD newborn screening in the state of New York beginning on 30 December 2013. Follow-up guidelines that have been established in New York are outlined. Based on the success of newborn screening in New York, and early results in Connecticut, where X-ALD newborn screening started in December 2015, and in California, where X-ALD newborn screening began in September 2016, we are confident and hopeful that X-ALD newborn screening will expand to include all US states and to countries that have established neonatal screening programs. The Minster of Health in the Netherlands has approved the addition of X-ALD to the newborn screening program with a start date expected in 2017. The states, such as Massachusetts, Illinois, Minnesota, New Jersey, Florida and Washington, that have legislative approval will commence screening as soon as budgetary resources, testing and follow-up procedures are in place.

Original languageEnglish (US)
Article number15
JournalInternational Journal of Neonatal Screening
Volume2
Issue number4
DOIs
StatePublished - Dec 2016

Fingerprint

Adrenoleukodystrophy
Neonatal Screening
Adrenal Insufficiency
Cell Transplantation
Netherlands
Health Services
Early Diagnosis
History
Guidelines

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Microbiology (miscellaneous)
  • Obstetrics and Gynecology

Cite this

Moser, A. B., Jones, R. O., Hubbard, W. C., Tortorelli, S., Orsini, J. J., Caggana, M., ... Raymond, G. V. (2016). Newborn screening for X-Linked adrenoleukodystrophy. International Journal of Neonatal Screening, 2(4), [15]. https://doi.org/10.3390/ijns2040015
Moser, Ann B. ; Jones, Richard O. ; Hubbard, Walter C. ; Tortorelli, Silvia ; Orsini, Joseph J. ; Caggana, Michele ; Vogel, Beth H. ; Raymond, Gerald V. / Newborn screening for X-Linked adrenoleukodystrophy. In: International Journal of Neonatal Screening. 2016 ; Vol. 2, No. 4.
@article{02fe74ba461a47acb46d1a79f9fecc6b,
title = "Newborn screening for X-Linked adrenoleukodystrophy",
abstract = "Early diagnosis of males with X-linked adrenoleukodystrophy (X-ALD) is essential for preventing loss of life due to adrenal insufficiency and for timely therapy of the childhood cerebral form of X-ALD with hematopoietic cell transplantation. This article describes X-ALD, the current therapies, the history of the development of the newborn screening test, the approval by the Secretary of Health and Human Services for the addition of X-ALD newborn screening to the recommended uniform panel of disorders screened as newborns (RUSP) and the successful implementation of X-ALD newborn screening in the state of New York beginning on 30 December 2013. Follow-up guidelines that have been established in New York are outlined. Based on the success of newborn screening in New York, and early results in Connecticut, where X-ALD newborn screening started in December 2015, and in California, where X-ALD newborn screening began in September 2016, we are confident and hopeful that X-ALD newborn screening will expand to include all US states and to countries that have established neonatal screening programs. The Minster of Health in the Netherlands has approved the addition of X-ALD to the newborn screening program with a start date expected in 2017. The states, such as Massachusetts, Illinois, Minnesota, New Jersey, Florida and Washington, that have legislative approval will commence screening as soon as budgetary resources, testing and follow-up procedures are in place.",
author = "Moser, {Ann B.} and Jones, {Richard O.} and Hubbard, {Walter C.} and Silvia Tortorelli and Orsini, {Joseph J.} and Michele Caggana and Vogel, {Beth H.} and Raymond, {Gerald V.}",
year = "2016",
month = "12",
doi = "10.3390/ijns2040015",
language = "English (US)",
volume = "2",
journal = "International Journal of Neonatal Screening",
issn = "2409-515X",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "4",

}

Moser, AB, Jones, RO, Hubbard, WC, Tortorelli, S, Orsini, JJ, Caggana, M, Vogel, BH & Raymond, GV 2016, 'Newborn screening for X-Linked adrenoleukodystrophy', International Journal of Neonatal Screening, vol. 2, no. 4, 15. https://doi.org/10.3390/ijns2040015

Newborn screening for X-Linked adrenoleukodystrophy. / Moser, Ann B.; Jones, Richard O.; Hubbard, Walter C.; Tortorelli, Silvia; Orsini, Joseph J.; Caggana, Michele; Vogel, Beth H.; Raymond, Gerald V.

In: International Journal of Neonatal Screening, Vol. 2, No. 4, 15, 12.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Newborn screening for X-Linked adrenoleukodystrophy

AU - Moser, Ann B.

AU - Jones, Richard O.

AU - Hubbard, Walter C.

AU - Tortorelli, Silvia

AU - Orsini, Joseph J.

AU - Caggana, Michele

AU - Vogel, Beth H.

AU - Raymond, Gerald V.

PY - 2016/12

Y1 - 2016/12

N2 - Early diagnosis of males with X-linked adrenoleukodystrophy (X-ALD) is essential for preventing loss of life due to adrenal insufficiency and for timely therapy of the childhood cerebral form of X-ALD with hematopoietic cell transplantation. This article describes X-ALD, the current therapies, the history of the development of the newborn screening test, the approval by the Secretary of Health and Human Services for the addition of X-ALD newborn screening to the recommended uniform panel of disorders screened as newborns (RUSP) and the successful implementation of X-ALD newborn screening in the state of New York beginning on 30 December 2013. Follow-up guidelines that have been established in New York are outlined. Based on the success of newborn screening in New York, and early results in Connecticut, where X-ALD newborn screening started in December 2015, and in California, where X-ALD newborn screening began in September 2016, we are confident and hopeful that X-ALD newborn screening will expand to include all US states and to countries that have established neonatal screening programs. The Minster of Health in the Netherlands has approved the addition of X-ALD to the newborn screening program with a start date expected in 2017. The states, such as Massachusetts, Illinois, Minnesota, New Jersey, Florida and Washington, that have legislative approval will commence screening as soon as budgetary resources, testing and follow-up procedures are in place.

AB - Early diagnosis of males with X-linked adrenoleukodystrophy (X-ALD) is essential for preventing loss of life due to adrenal insufficiency and for timely therapy of the childhood cerebral form of X-ALD with hematopoietic cell transplantation. This article describes X-ALD, the current therapies, the history of the development of the newborn screening test, the approval by the Secretary of Health and Human Services for the addition of X-ALD newborn screening to the recommended uniform panel of disorders screened as newborns (RUSP) and the successful implementation of X-ALD newborn screening in the state of New York beginning on 30 December 2013. Follow-up guidelines that have been established in New York are outlined. Based on the success of newborn screening in New York, and early results in Connecticut, where X-ALD newborn screening started in December 2015, and in California, where X-ALD newborn screening began in September 2016, we are confident and hopeful that X-ALD newborn screening will expand to include all US states and to countries that have established neonatal screening programs. The Minster of Health in the Netherlands has approved the addition of X-ALD to the newborn screening program with a start date expected in 2017. The states, such as Massachusetts, Illinois, Minnesota, New Jersey, Florida and Washington, that have legislative approval will commence screening as soon as budgetary resources, testing and follow-up procedures are in place.

UR - http://www.scopus.com/inward/record.url?scp=85032985304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032985304&partnerID=8YFLogxK

U2 - 10.3390/ijns2040015

DO - 10.3390/ijns2040015

M3 - Article

AN - SCOPUS:85032985304

VL - 2

JO - International Journal of Neonatal Screening

JF - International Journal of Neonatal Screening

SN - 2409-515X

IS - 4

M1 - 15

ER -

Moser AB, Jones RO, Hubbard WC, Tortorelli S, Orsini JJ, Caggana M et al. Newborn screening for X-Linked adrenoleukodystrophy. International Journal of Neonatal Screening. 2016 Dec;2(4). 15. https://doi.org/10.3390/ijns2040015